Patrick M Wheeler Net Worth

The estimated Net Worth of Patrick M Wheeler is at least 254 千$ dollars as of 18 September 2014. Patrick Wheeler owns over 8,246 units of ARCA biopharma Inc stock worth over 243,624$ and over the last 15 years Patrick sold ABIO stock worth over 10,802$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Patrick Wheeler ABIO stock SEC Form 4 insiders trading

Patrick has made over 1 trades of the ARCA biopharma Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Patrick sold 8,246 units of ABIO stock worth 10,802$ on 18 September 2014.

The largest trade Patrick's ever made was selling 8,246 units of ARCA biopharma Inc stock on 18 September 2014 worth over 10,802$. On average, Patrick trades about 1,649 units every 0 days since 2010. As of 18 September 2014 Patrick still owns at least 101,510 units of ARCA biopharma Inc stock.

You can see the complete history of Patrick Wheeler stock trades at the bottom of the page.

What's Patrick Wheeler's mailing address?

Patrick's mailing address filed with the SEC is C/O ARCA BIOPHARMA, INC., 8001 ARISTA PLACE, SUITE 200, BROOMFIELD, CO, 80021.

Insiders trading at ARCA biopharma Inc

Over the last 16 years, insiders at ARCA biopharma Inc have traded over 9,048,465$ worth of ARCA biopharma Inc stock and bought 3,605,825 units worth 6,507,167$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Anthony A. Jr. Florence. On average, ARCA biopharma Inc executives and independent directors trade stock every 54 days with the average trade being worth of 636,994$. The most recent stock trade was executed by Henderson Group Plc Janus H... on 16 August 2024, trading 5,818 units of ABIO stock currently worth 17,047$.

What does ARCA biopharma Inc do?

arca was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. arca’s lead development program is intended to be a direct implementation of those ideas. gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (af). arca has identified genetic variations in cardiac receptors that we believe may predict individual patient response to gencaro™, giving gencaro™ the potential to be the first genetically-targeted prevention treatment for af.

Complete history of Patrick Wheeler stock trades at ARCA biopharma Inc

ARCA biopharma Inc executives and stock owners

ARCA biopharma Inc executives and other stock owners filed with the SEC include:

• Michael Bristow,
  President, Chief Executive Officer, Director
• Dr. Michael R. Bristow M.D., Ph.D.,
  Co-Founder, Pres, CEO & Director
• Thomas A. Keuer,
  Chief Operating Officer
• Christopher Ozeroff,
  Senior Vice President, General Counsel, Secretary
• Christopher D. Ozeroff,
  Sr. VP, Gen. Counsel & Sec.
• Raymond Woosley,
  Director
• Daniel Mitchell,
  Director
• Anders Hove,
  Director
• Linda Grais,
  Lead Independent Director
• Brian Selby,
  Chief Accounting Officer, Principal Accounting Officer, Vice President - Finance
• Thomas Keuer,
  Chief Operating Officer
• Robert Conway,
  Chairman of the Board
• Dr. Debra Marshall FACC, M.D.,
  Chief Medical Officer
• C. Jeffrey Dekker,
  Chief Financial Officer
• Henderson Group Plc Janus H...,
  
• Ravi Viswanathan,
  10% owner
• Scott D Sandell,
  10% owner
• David M Mott,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Peter J Barris,
  10% owner
• Healthcare Capital Partners...,
  
• Peter W. Sonsini,
  10% owner
• Jon Sakoda,
  10% owner
• Joshua Makower,
  10% owner
• Forest Baskett,
  10% owner
• Equity Opportunities Fund I...,
  
• Jean Francois Formela,
  Director
• Kathryn E Falberg,
  CFO and COO
• J William Freytag,
  Director
• Mary K Pendergast,
  Director
• Patrick M Wheeler,
  acting Chief Financial Officer
• Riley Mccormack,
  10% owner
• David George Lowe,
  Director
• Burton E Sobel,
  Director
• Venture Fund Vii L P Atlas,
  10% owner
• Richard B Brewer,
  Director
• John L Zabriskie,
  Director
• Venture Partners Qualified ...,
  10% owner
• Ted W Love,
  Director
• Funds, Lp Ma Weaver Jacob F...,
  
• Jacob Ma Weaver,
  
• Fund, Lp Funicular,
  
• C. Jeffrey Dekker,
  Chief Financial Officer
• Fund, Lp Ma Weaver Jacob Fu...,
  
• Funds, Lp Funicular,
  10% owner
• James P Flynn,
  Director